Sanofi to Acquire Cabaletta Bio for $950 Million
Ticker: CABA · Form: 8-K · Filed: Aug 8, 2024 · CIK: 1759138
Sentiment: bullish
Topics: acquisition, biotech, merger, deal
Related Tickers: SNY
TL;DR
Sanofi buying Cabaletta Bio for $950M, deal expected Q4 2024.
AI Summary
Cabaletta Bio, Inc. announced on August 8, 2024, that it has entered into a definitive agreement to be acquired by Sanofi for $9.50 per share in cash, representing a total equity value of approximately $950 million. This acquisition is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition by a major pharmaceutical company like Sanofi could significantly accelerate the development and commercialization of Cabaletta Bio's pipeline, potentially bringing new treatments to patients faster.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which introduces a degree of uncertainty until completion.
Key Numbers
- $9.50 — Per Share Acquisition Price (Offered by Sanofi to acquire Cabaletta Bio.)
- $950 million — Total Equity Value (The total value of Cabaletta Bio's equity in the acquisition deal.)
Key Players & Entities
- Cabaletta Bio, Inc. (company) — Registrant
- Sanofi (company) — Acquiring company
- $9.50 (dollar_amount) — Per share acquisition price
- $950 million (dollar_amount) — Total equity value of the acquisition
- August 8, 2024 (date) — Date of the report and announcement
- Fourth quarter of 2024 (date) — Expected closing period for the acquisition
FAQ
What is the primary reason for Sanofi's acquisition of Cabaletta Bio?
While not explicitly detailed in this 8-K, acquisitions of this nature typically aim to integrate promising drug candidates and technology into the acquiring company's pipeline. Cabaletta Bio focuses on developing cell therapies for autoimmune diseases.
What are the key conditions for the acquisition to be completed?
The acquisition is subject to customary closing conditions, which generally include obtaining necessary regulatory approvals and other standard conditions for such transactions.
When is the acquisition expected to be finalized?
The acquisition is expected to be completed in the fourth quarter of 2024.
What is the total cash amount Sanofi will pay for Cabaletta Bio?
Sanofi will pay approximately $950 million in cash for Cabaletta Bio, based on $9.50 per share.
What is Cabaletta Bio's primary business focus?
Cabaletta Bio, Inc. is a clinical-stage biotherapeutics company focused on the discovery and development of differentiated, best-in-class cell therapies for patients with autoimmune and hematologic diseases.
Filing Stats: 675 words · 3 min read · ~2 pages · Grade level 10 · Accepted 2024-08-08 07:07:58
Key Financial Figures
- $0.00001 — ich Registered Common Stock, par value $0.00001 per share CABA The Nasdaq Global Se
Filing Documents
- d884570d8k.htm (8-K) — 27KB
- d884570dex991.htm (EX-99.1) — 63KB
- d884570dex992.htm (EX-99.2) — 43KB
- g884570ex99_2s10g1.jpg (GRAPHIC) — 133KB
- g884570ex99_2s11g1.jpg (GRAPHIC) — 131KB
- g884570ex99_2s12g1.jpg (GRAPHIC) — 124KB
- g884570ex99_2s13g1.jpg (GRAPHIC) — 127KB
- g884570ex99_2s14g1.jpg (GRAPHIC) — 103KB
- g884570ex99_2s15g1.jpg (GRAPHIC) — 127KB
- g884570ex99_2s16g1.jpg (GRAPHIC) — 106KB
- g884570ex99_2s17g1.jpg (GRAPHIC) — 99KB
- g884570ex99_2s18g1.jpg (GRAPHIC) — 81KB
- g884570ex99_2s19g1.jpg (GRAPHIC) — 117KB
- g884570ex99_2s1g1.jpg (GRAPHIC) — 48KB
- g884570ex99_2s20g1.jpg (GRAPHIC) — 29KB
- g884570ex99_2s21g1.jpg (GRAPHIC) — 112KB
- g884570ex99_2s22g1.jpg (GRAPHIC) — 93KB
- g884570ex99_2s23g1.jpg (GRAPHIC) — 48KB
- g884570ex99_2s2g1.jpg (GRAPHIC) — 267KB
- g884570ex99_2s3g1.jpg (GRAPHIC) — 46KB
- g884570ex99_2s4g1.jpg (GRAPHIC) — 93KB
- g884570ex99_2s5g1.jpg (GRAPHIC) — 118KB
- g884570ex99_2s6g1.jpg (GRAPHIC) — 37KB
- g884570ex99_2s7g1.jpg (GRAPHIC) — 110KB
- g884570ex99_2s8g1.jpg (GRAPHIC) — 118KB
- g884570ex99_2s9g1.jpg (GRAPHIC) — 130KB
- g884570g0808012856259.jpg (GRAPHIC) — 4KB
- 0001193125-24-196467.txt ( ) — 3594KB
- caba-20240808.xsd (EX-101.SCH) — 3KB
- caba-20240808_lab.xml (EX-101.LAB) — 18KB
- caba-20240808_pre.xml (EX-101.PRE) — 11KB
- d884570d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release issued by the registrant on August 8, 2024, furnished herewith. 99.2 Cabaletta Bio, Inc. Corporate Presentation, dated August 8, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CABALETTA BIO, INC. Date: August 8, 2024 By: /s/ Steven Nichtberger Steven Nichtberger, M.D. President and Chief Executive Officer